Endobronchial Ultrasound Biopsy Market Size and Forecast 2025–2033

Introduction

The global healthcare industry is witnessing a profound shift toward minimally invasive diagnostic technologies, particularly in oncology and respiratory medicine. Among these advancements, endobronchial ultrasound (EBUS) biopsy has emerged as a critical tool for accurate, real-time diagnosis and staging of pulmonary diseases. As lung cancer and chronic respiratory conditions continue to rise worldwide, EBUS-guided biopsy procedures are gaining widespread clinical acceptance.

According to Renub Research, the Endobronchial Ultrasound Biopsy Market is expected to grow from US$ 820 million in 2024 to US$ 1,275.36 million by 2033, registering a compound annual growth rate (CAGR) of 5.03% between 2025 and 2033. This steady expansion reflects the increasing demand for precise diagnostic solutions that minimize patient risk while improving clinical outcomes.

Download Free Sample Report

Market Overview of Endobronchial Ultrasound Biopsy (EBUS)

Endobronchial ultrasound biopsy is a minimally invasive diagnostic procedure that allows physicians to visualize and sample lung tissue and mediastinal lymph nodes using real-time ultrasound guidance. It has become a preferred alternative to traditional surgical biopsies, particularly for non-small cell lung cancer (NSCLC) staging and diagnosis of thoracic malignancies.

EBUS offers several clinical advantages, including reduced procedural risk, shorter recovery times, lower complication rates, and improved diagnostic accuracy in hard-to-reach lesions. These benefits have positioned EBUS as a cornerstone technology in modern pulmonary and oncology diagnostics.

The market’s expansion is being driven by technological advancements in ultrasound imaging, improved needle design, enhanced visualization capabilities, and the availability of integrated imaging systems. Leading manufacturers such as Olympus Corporation, Boston Scientific, Cook Medical, Medtronic, FUJIFILM, and GE Healthcare continue to invest heavily in research, development, and clinical trials to improve device performance and procedural outcomes.

Epidemiological and Demographic Factors Driving Market Growth

One of the strongest catalysts for EBUS biopsy market growth is the rising global burden of lung cancer. Lung cancer remains one of the leading causes of cancer-related mortality worldwide, largely attributed to smoking, environmental pollution, occupational hazards, and lifestyle factors.

In addition, the aging global population significantly contributes to market expansion. According to the World Health Organization (WHO), the global population aged 60 years and above is expected to reach 1.4 billion by 2030, up from approximately 1.1 billion in 2021. Older populations are more susceptible to cancer and chronic respiratory diseases, increasing the need for advanced diagnostic procedures like EBUS.

Beyond cancer, the increasing prevalence of tuberculosis (TB), chronic obstructive pulmonary disease (COPD), and interstitial lung diseases has further strengthened demand for minimally invasive pulmonary diagnostic techniques.

Key Growth Drivers in the Endobronchial Ultrasound Biopsy Market

Rising Incidence of Lung Cancer

Lung cancer, particularly NSCLC, accounts for a significant proportion of global cancer diagnoses. Early and accurate staging is critical for selecting appropriate treatment strategies, including surgery, chemotherapy, radiation therapy, and targeted therapies.

EBUS-guided biopsy enables precise lymph node sampling, allowing clinicians to determine disease stage with high accuracy while avoiding invasive surgical procedures. As lung cancer incidence continues to rise globally, the demand for EBUS-guided diagnostics is expected to grow steadily.

Shift Toward Minimally Invasive Procedures

Healthcare systems worldwide are increasingly prioritizing minimally invasive procedures due to their benefits in reducing patient morbidity, hospital stays, and overall healthcare costs. Compared to conventional surgical biopsies, EBUS procedures can be performed under moderate sedation, significantly lowering procedural risk and improving patient comfort.

This shift aligns with broader healthcare trends emphasizing value-based care, faster recovery, and improved patient experience, making EBUS a preferred diagnostic modality.

Increasing Adoption in Emerging Markets

Emerging economies are rapidly expanding their healthcare infrastructure and diagnostic capabilities. Government investments, public–private partnerships, and growing awareness of early cancer detection are accelerating the adoption of EBUS technology across Asia-Pacific, Latin America, and parts of the Middle East and Africa.

As access to advanced diagnostic tools improves and training programs expand, emerging markets are expected to represent a significant share of future EBUS biopsy market growth.

Challenges Limiting Market Expansion

High Equipment and Maintenance Costs

Despite its clinical advantages, EBUS technology involves substantial upfront investment. The cost of EBUS scopes, ultrasound processors, imaging systems, specialized needles, and accessories can be prohibitive for smaller hospitals and clinics. Ongoing maintenance, software upgrades, and consumables further increase operational costs.

These financial barriers can delay adoption, particularly in resource-constrained healthcare settings.

Limited Availability of Skilled Professionals

Successful EBUS procedures require specialized training and expertise. A shortage of trained pulmonologists and technicians—especially in rural areas and developing regions—limits the widespread implementation of EBUS technology. Operator skill plays a crucial role in diagnostic accuracy, and insufficient training may result in suboptimal outcomes.

Addressing this challenge will require expanded training programs, clinical workshops, and institutional support.

Regional Market Insights

United States Endobronchial Ultrasound Biopsy Market

The United States represents one of the largest and most technologically advanced EBUS biopsy markets globally. The high prevalence of lung cancer, robust healthcare infrastructure, favorable reimbursement frameworks, and rapid adoption of innovative medical technologies support strong market growth.

According to the American Cancer Society, lung and bronchus cancer remains one of the most commonly diagnosed cancers in the U.S., reinforcing the need for precise and minimally invasive diagnostic solutions like EBUS.

United Kingdom Endobronchial Ultrasound Biopsy Market

In the UK, the increasing burden of lung diseases and strong public healthcare support have driven steady adoption of EBUS biopsy procedures. The National Health Service (NHS) has emphasized early cancer detection and minimally invasive diagnostics, contributing to market expansion. However, equipment costs and workforce training requirements remain key challenges.

India Endobronchial Ultrasound Biopsy Market

India’s EBUS biopsy market is experiencing rapid growth due to rising lung cancer incidence, expanding private healthcare networks, and increasing awareness of advanced diagnostic methods. Government healthcare initiatives and medical tourism also play an important role in accelerating adoption, although cost constraints and uneven access remain limiting factors.

Saudi Arabia Endobronchial Ultrasound Biopsy Market

Saudi Arabia is witnessing growing demand for EBUS biopsy procedures as part of its broader healthcare modernization efforts. Investments under national healthcare transformation programs are improving access to advanced diagnostic technologies. However, similar to other emerging markets, high device costs and specialized training requirements may slow uniform adoption.

Recent Developments in the Endobronchial Ultrasound Biopsy Industry

Recent industry developments highlight the continued innovation and investment shaping the EBUS biopsy market:

October 2024: GE Healthcare announced an expansion of its medical imaging manufacturing facilities in Wisconsin, aiming to meet rising global demand for advanced ultrasound and imaging systems.

September 2024: FUJIFILM Healthcare Europe introduced compatibility enhancements for its ARIETTA 750 FF ENDO ultrasound system, improving visualization and imaging precision for EBUS procedures.

October 2023: Praxis received FDA approval for its EndoCore EBUS-TBNA biopsy device, designed to enhance tissue sampling accuracy and procedural efficiency.

These developments underscore the industry’s focus on improving diagnostic accuracy, workflow efficiency, and patient outcomes.

Endobronchial Ultrasound Biopsy Market Segmentation

By Product

EBUS Scopes

EBUS Needles

Ultrasound Processors and Imaging Systems

Accessories

By Application

Cancer Diagnostics

Infection Diagnostics

Others

By End Use

Hospitals

Ambulatory Surgical Centers (ASCs)

Specialty Clinics

By Region

North America: United States, Canada

Europe: France, Germany, Italy, Spain, United Kingdom, Belgium, Netherlands, Turkey

Asia Pacific: China, Japan, India, Australia, South Korea, Thailand, Malaysia, Indonesia, New Zealand

Latin America: Brazil, Mexico, Argentina

Middle East & Africa: Saudi Arabia, United Arab Emirates, South Africa

Competitive Landscape

The Endobronchial Ultrasound Biopsy market is moderately consolidated, with major players competing through product innovation, strategic partnerships, and geographic expansion. Key companies profiled include:

GE Healthcare

Siemens Healthcare Private Limited

Koninklijke Philips N.V.

Boston Scientific Corporation

Olympus Corporation

Cook Group Incorporated

FUJIFILM Holdings Corporation

Medi-Globe Technologies GmbH

Each company is evaluated across five viewpoints: overview, key personnel, recent developments and strategies, revenue analysis, and overall company performance.

Final Thoughts

The Endobronchial Ultrasound Biopsy Market is set for sustained growth through 2033, driven by the rising global burden of lung cancer, increasing preference for minimally invasive diagnostics, and continuous technological advancements. While challenges related to cost and skilled workforce availability persist, ongoing innovation and healthcare infrastructure development—particularly in emerging markets—are expected to unlock new growth opportunities.

As precision medicine and early diagnosis become central to modern healthcare, EBUS biopsy technology will continue to play a pivotal role in improving patient outcomes and shaping the future of pulmonary diagnostics.